CUET UG Biology Booster Test 3-Molecular Diagnostics & Transgenic Animals

In diagnostic biology, symptoms are physiological manifestations that occur when pathogen proliferation has reached a threshold high enough to damage host tissues or trigger massive immune responses. Relying on these prevents "early diagnosis." Option A is correct because early treatment is contingent upon intercepting the pathogen at a low concentration, which is only possible via molecular tools, not symptom-based clinical assessment.

The fundamental "early" advantage of PCR and ELISA lies in their molecular sensitivity. PCR amplifies pathogen DNA, and ELISA exploits highly specific antigen-antibody binding. Option B correctly identifies these as the mechanisms that allow detection of minute quantities of pathogen markers, which is the definition of early diagnostic capability.

When pathogen concentration is very low (early stage), standard clinical methods fail, so we use PCR to amplify the DNA (1-ii). When concentration is high, conventional clinical methods (serum/urine analysis) can easily detect the pathogen or its effects (2-i).

In suspected AIDS patients, PCR is used to detect the viral genome (HIV RN A) even in trace amounts (1-ii). In suspected cancer patients, PCR is used to detect genetic mutations in the patient's own cellular DNA (2-i).

The logical biological sequence starts with infection/exposure (1), which causes the immune system to produce antibodies (2). The diagnostic test, ELISA, is then performed to detect these specific antibodies circulating in the host's serum (3).

The process begins with the presence of the pathogen (1). The pathogen then synthesizes characteristic proteins or glycoproteins (3) that serve as antigens. Finally, ELISA reagents specifically bind to these antigens (2) to produce a detectable signal.

Statement I is correct because radioactive tagging (like P-32) allows detection via film. Statement II is correct because the entire basis of this technique is the specificity of base pairing (hybridization). Statement III is correct; both ssDNA and ssRNA are commonly used as probes.

Statement I is the correct definition of autoradiography. Statement III is correct; if a gene is mutated, the probe—which is designed for the normal gene—will not find its complementary sequence and will not bind. Statement II is incorrect because if the gene hybridizes, it would appear; it fails to appear specifically because it fails to hybridize.

Option C is the "NOT" statement. Transgenic mice are vastly more prevalent than rats or rabbits, not because of size, but because of their reproductive speed, well-annotated genome, and established gene-editing protocols.

Option D is the critical misrepresentation. Transgenic mice are models for testing the safety of polio vaccines to ensure they are attenuated and safe for human use. They are not "factories" used to synthesize the vaccine itself.

Designing transgenic animals is a sophisticated tool for functional genomics and developmental biology. Options A, B, and D are standard objectives for understanding biological systems. Option C is entirely unrelated to scientific physiological inquiry and misrepresents the intended use of transgenic research models.

Transgenic models are created to modify specific genes (e.g., insulin-like growth factors) to observe the resulting biological changes. They are not methods to perform whole-genome repair or to erase all native background mutations, which would make the study of specific pathways impossible.

A cystic fibrosis transgenic model is designed to simulate the genetic and physiological defects found in human patients. The primary clinical value is that it provides a platform to test novel therapeutic interventions (drugs/gene therapies) before committing to human trials, ensuring safety and efficacy.

Transgenic animals serve as in vivo (inside the living organism) systems. This is the crucial bridge, as basic research (in vitro) often fails to capture the complexity of an entire organism. Testing treatments in these models is the standard step before beginning clinical applications (human trials).

Biopharming, or using transgenic animals to produce therapeutic proteins, is primarily driven by the need to scale up production of medicines that are difficult or expensive to synthesize. Producing alpha-1-antitrypsin in transgenic animals allows for high-yield collection of the protein, significantly reducing the cost and complexity of the medicine.

The NCERT text on biotechnology applications highlights that experiments are underway to produce products for the treatment of Phenylketonuria (PKU) and cystic fibrosis using transgenic animals, following the conceptual success of other protein-producing models.

Transgenic technology allowed scientists to introduce a human gene into the cow's mammary gland, causing the milk to contain human alpha-lactalbumin. This results in milk that is nutritionally closer to human milk, fulfilling the definition of a tailor-made, nutritionally superior food product.

A yield of 2.4 grams per litre is a robust level of protein expression. In biotechnology, this validates the success of the gene transfer and integration, showing that the human gene is not just present but is being expressed at a level that could have practical applications.

Toxicity testing requires detecting whether a substance is harmful. If an animal is engineered to be more sensitive to a substance, it will demonstrate signs of toxicity faster and with lower doses of the substance. This clarity in response makes the test more efficient and more reliable.

In pharmaceuticals, the path from discovery to approval is time-sensitive. Reduced testing time in transgenic models is a competitive advantage because it allows companies to validate the safety of new chemicals or drugs significantly faster, potentially saving months or years in the development pipeline.